Astellas Pharma Inc. / Ogeda SA

Menopausal Vasomotor Symptoms (Hot Flashes)

1.5M US cases/yr

Disease Overview

Vasomotor symptoms (hot flashes and night sweats) are the most common and disruptive symptoms of menopause, driven by hypothalamic KNDy-neuron dysregulation as estrogen declines. Up to 80% of menopausal women experience VMS, with average duration of 7-10 years and substantial impact on sleep, mood and work productivity. For decades the only effective therapy was menopausal hormone therapy, which carries cardiovascular and breast cancer risks documented by the Women's Health Initiative — leaving a large unmet need for non-hormonal options.

Competitive Landscape

At deal time (April 2017) the VMS market was dominated by hormone therapy (Premarin, Prempro, Estrace, Climara) and off-label use of paroxetine (Brisdelle, the only non-hormonal FDA-approved option), gabapentin and SSRIs/SNRIs — all with modest efficacy or significant side effects. Ogeda's fezolinetant, a selective NK3 receptor antagonist, was the lead asset in a new mechanistic class targeting KNDy neurons in the hypothalamus to directly address the thermoregulatory dysfunction underlying hot flashes — a fundamentally non-hormonal approach that sidestepped WHI-era safety concerns. Bayer's elinzanetant (NK1/NK3 dual antagonist) was the principal pipeline rival, and the Astellas-Ogeda deal triggered a mini arms race in NK3-class development. Fezolinetant ultimately won the class race with Veozah's FDA approval in May 2023 (first non-hormonal NK3 approved for VMS), although a 2024 boxed warning for hepatotoxicity has tempered uptake. The deal also redrew Astellas' women's health franchise, complementing the Mirabegron OAB business with a launch-ready VMS asset.